These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8237027)

  • 1. New therapies for multiple sclerosis--when?
    Waisbren BA
    Wis Med J; 1993 Aug; 92(8):448-50. PubMed ID: 8237027
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current therapy of multiple sclerosis: "T-cell vaccination"].
    Zipp F; Hohlfeld R
    Nervenarzt; 1994 Jun; 65(6):424-5. PubMed ID: 8072598
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current therapy of multiple sclerosis. Oral tolerance induction to myelin antigens].
    Voltz R; Hohlfeld R
    Nervenarzt; 1993 Jun; 64(6):411-2. PubMed ID: 8332235
    [No Abstract]   [Full Text] [Related]  

  • 4. Antimyelin basic protein antibodies and cellular hypersensitivity in multiple sclerosis.
    Sheremata W; Wood DD; Moscarello MA
    Trans Am Neurol Assoc; 1976; 101():291-4. PubMed ID: 1028264
    [No Abstract]   [Full Text] [Related]  

  • 5. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
    Karussis D; Slavin S
    J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific immunotherapy: one size does not fit all.
    Genain CP; Zamvil SS
    Nat Med; 2000 Oct; 6(10):1098-100. PubMed ID: 11017135
    [No Abstract]   [Full Text] [Related]  

  • 8. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
    Fontoura P; Garren H; Steinman L
    Int Rev Immunol; 2005; 24(5-6):415-46. PubMed ID: 16318989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune augmenting therapy as treatment of multiple sclerosis. Warning regarding a potentially toxic alternative treatment method].
    Pette M; Hartung HP; Toyka KV
    Nervenarzt; 1994 Dec; 65(12):878-90. PubMed ID: 7854511
    [No Abstract]   [Full Text] [Related]  

  • 10. [Perspectives in multiple sclerosis research].
    Lassmann H
    Wien Med Wochenschr; 1996; 146(19-20):528-32. PubMed ID: 9082653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current findings on the pathogenesis of multiple sclerosis].
    Steck A
    Krankenpfl Soins Infirm; 1981 Jul; (7):57. PubMed ID: 6265695
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunobiology of oligodendrocytes in multiple sclerosis.
    Ruffini F; Chojnacki A; Weiss S; Antel JP
    Adv Neurol; 2006; 98():47-63. PubMed ID: 16400826
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
    Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future immunotherapies in multiple sclerosis.
    Blevins G; Martin R
    Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-specific therapies in multiple sclerosis.
    Sospedra M; Martin R
    Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospects of an immunologic therapy of multiple sclerosis].
    Fasanaro G; Gentile A; Stella L
    Acta Neurol (Napoli); 1972; 27(4):367-78. PubMed ID: 5085161
    [No Abstract]   [Full Text] [Related]  

  • 18. Physiopathology of multiple sclerosis.
    Visconti A; Santucci S; Figà Talamanca L; Cannoni S; Ristori G; Salvetti M
    Neurol Sci; 2003 Dec; 24 Suppl 5():S287-90. PubMed ID: 14652791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunistic infections and other risks with newer multiple sclerosis therapies.
    Berger JR; Houff S
    Ann Neurol; 2009 Apr; 65(4):367-77. PubMed ID: 19399841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multiple sclerosis. Risk factors].
    Drăgănescu N
    Virologie; 1987; 38(3):223-34. PubMed ID: 3310380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.